Health Economics of Personalized Genomic Medicine Banner

Stratified genomic medicine is a new reality that brings tremendous advantages to the patients and some puzzling questions to pharmaceutical and biotech companies, healthcare providers and laboratories. The key questions are: who is going to pay for the innovation in pharma and healthcare, and how we can measure the cost-benefit ratio while providing state of art care. Health Economics of Personalized Genomic Medicine is designed to bring together major stakeholders and to search for the answers to these pressing questions.

Day 1 | Day 2 | Download Brochure 

Tuesday, November 18

8:00 am Morning Coffee


LEARNING HEALTHCARE SYSTEM
 

8:40 Chairperson’s Opening Remarks 

Brian Kennedy, Executive Director, Alliance for Patient Access 

8:45 The Department of Veterans Affairs Efforts towards Creating a Learning Healthcare System

Mary Brophy M.D., MPH, Attending Oncologist, VA Boston Healthcare System

The Department of Veterans Affairs Healthcare System offers a unique opportunity to explore the logistics and feasibility of creating a learning healthcare environment. Features of the system that support such an effort include utilization of a national electronic medical record, integration of research activities within most healthcare facilities and progressive clinical care and research leadership. Researchers and clinical care providers at the Boston VA Medical Center can currently apply business intelligence (BI) tools to national medical record data to allow for enhanced clinical care and research activities. Through the Point-of-Care Research (POCR) Program pragmatic clinical trials are conducted within the clinical care ecosystem almost entirely within the electronic medical record application.

9:15 Precision Oncology Program at Veteran Affairs Cancer Center

 LouisFioreLouis Fiore, M.D., MPH, Professor of Medicine, Boston University School of Medicine, Professor of Public Health, Boston University School of Public Health, Executive Director, Massachusetts Veterans Epidemiology Research and Information Center at Department of Veterans Affairs 

The Precision Oncology Program utilizes these tools described in the previous presentation to make available precision therapy to cancer patients.

9:45 Physicians Advocating for Patient Access

BrianKennedyBrian Kennedy, Executive Director, Alliance for Patient Access

Brian Kennedy is Executive Director of the Alliance for Patient Access, a national network which advocates for patient access to approved therapies and appropriate clinical care. Mr. Kennedy will explain how since 2006, AfPA has successfully trained, organized and mobilized physicians to engage policymakers and the media on health policy issues impacting the physician-patient relationship.

10:15 Q&A with Speakers

10:30 Networking Coffee Break

TOOLS FOR GENERATING AND SYNTHESIZING EVIDENCE 

11:00 Synthesizing and Applying Evidence for Decision-Making

SusanSnyderSusan R. Snyder, Ph.D., MBA, Research Investigator II/ Health Economist, Geisinger Center for Health Research

The goal of comprehensive and transparent approaches to valuation and decision-making in healthcare including pharmacogenomics has generated alternative decision-making frameworks relevant to investment, authorization, prescription, reimbursement, and resource allocation. This presentation will review the nature and application of evidence synthesis to support healthcare decision-making including the use of a flexible and valuable tool, multi-criteria decision analysis (MCDA).

11:30 Evaluating the Medical Utility of a Biomarker or Biomarker Score Test for Informing Treatment Decision

RichardSimonRichard Simon, Ph.D., Chief, Biometric Research Branch, NCI

A biomarker has medical utility if it informs treatment decisions in a manner that results in improved patient outcome compared to using standard of care diagnostics. Establishing the medical utility of a test is much more demanding than merely establishing that a test is prognostic. Prognostic tests can have medical utility but most do not. Medical utility must be established for each specific medical decision context, i.e. indication. I will discuss how to evaluate whether a test has medical utility for a specified indicate.

12:00 pm Close of Conference

Day 1 | Day 2 | Download Brochure 

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag